The cholinergic system in the pathophysiology and treatment of Alzheimer's disease

Brain

Volumn 141, Issue 7, 2018, Pages 1917-1933

  Hampel, Harald ^a,b,c   Mesulam, M Marsel ^d   Cuello, A Claudio ^e   Farlow, Martin R ^f   Giacobini, Ezio ^g   Grossberg, George T ^h   Khachaturian, Ara S ⁱ   Vergallo, Andrea ^a,b,c   Cavedo, Enrica ^a,b,c   Snyder, Peter J ^j,k   Khachaturian, Zaven S ⁱ  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020)   (United States)

^j BROWN UNIVERSITY   (United States)

^k UNIVERSITY OF RHODE ISLAND   (United States)

more..

Author keywords

acetylcholine; Alzheimer's disease; cholinergic system; cholinesterase inhibitors; cognition

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MUSCARINIC AGENT; NOOTROPIC AGENT; RIVASTIGMINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN FUNCTION; CHOLINERGIC NERVE CELL; CHOLINERGIC SYNAPSE; CHOLINERGIC SYSTEM; CORPUS STRIATUM; DEGENERATION; DENERVATION; FOLLOW UP; FOREBRAIN; GENETIC RISK; HUMAN; LIMBIC SYSTEM; NEOCORTEX; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROANATOMY; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THALAMUS; TREATMENT OUTCOME; COGNITION; COGNITIVE DEFECT; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHOLINERGIC AGENTS; CHOLINERGIC NEURONS; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; HUMANS; NEUROFIBRILLARY TANGLES;

EID: 85048969248     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awy132     Document Type: Review

References (172)

1. Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions. Int J Clin Pract 2014; 68: 465-70.
2. Arahata H, Ohyagi Y, Matsumoto S, Furuya H, Murai H, Kuwabara Y, et al. A patient with probable dementia with Lewy bodies, who showed improvement of dementia and parkinsonism by the administratim of donepezil [in Japanese]. Rinsho Shinkeigaku 2001; 41: 402-6.
3. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural circuit for circadian regulation of arousal. Nat Neurosci 2001; 4: 732-8.
4. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-21.
5. Auerbach JM, Segal M. Muscarinic receptors mediating depression and long-term potentiation in rat hippocampus. J Physiol 1996; 492 (Pt 2): 479-93.
6. Barbelivien A, MacKenzie ET, Dauphin F. Regional cerebral blood flow responses to neurochemical stimulation of the substantia innominata in the anaesthetized rat. Neurosci Lett 1995; 190: 81-4.
7. Beach TG, Kuo YM, Spiegel K, Emmerling MR, Sue LI, Kokjohn K, et al. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 308-13.
8. Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 2012; 37: 7-16.
9. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-60.
10. Blitzer RD, Gil O, Landau EM. Cholinergic stimulation enhances longterm potentiation in the CA1 region of rat hippocampus. Neurosci Lett 1990; 119: 207-10.
11. Bodiga V, Bodiga S. Renin angiotensin system in cognitive function and dementia. Asian J Neurosci 2013; 2013: 102602.
12. Bott JB, Heraud C, Cosquer B, Herbeaux K, Aubert J, Sartori M, et al. APOE-sensitive cholinergic sprouting compensates for hippocampal dysfunctions due to reduced entorhinal input. J Neurosci 2016; 36: 10472-86.
13. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitterrelated enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459-96.
14. Braak H, Del Tredici K. Reply: the early pathological process in sporadic Alzheimer's disease. Acta Neuropathol 2013; 126: 615-18.
15. Brewer L, Bennett K, McGreevy C, Williams D. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol 2013; 69: 1467-75.
16. Cattaneo A, Calissano P. Nerve growth factor and Alzheimer's disease: new facts for an old hypothesis. Mol Neurobiol 2012; 46: 588-604.
17. Cavedo E, Dubois B, Colliot O, Lista S, Croisile B, Tisserand GL, et al. Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer's disease. J Clin Psychiatry 2016; 77: e1631-8.
18. Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, et al. Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer's disease. Sci Rep 2017; 7: 11706.
19. Ceravolo R, Volterrani D, Frosini D, Bernardini S, Rossi C, Logi C, et al. Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J Neural Transm 2006; 113: 1787-90.
20. Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther 2013; 5: 21.
21. Chu J, Lauretti E, PraticoD. Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3b kinase: implications for Alzheimer's disease. Mol Psychiatry 2017; 22: 1002-8.
22. Cisse M, Braun U, Leitges M, Fisher A, Pages G, Checler F, et al. ERK1-independent alpha-secretase cut of beta-amyloid precursor protein via M1 muscarinic receptors and PKCalpha/epsilon. Mol Cell Neurosci 2011; 47: 223-32.
23. Claassen J, Jansen R. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol A Biol Sci Med Sci 2006; 61: 267-71.
24. Collins AL, Aitken TJ, Greenfield VY, Ostlund SB, Wassum KM. Nucleus accumbens acetylcholine receptors modulate dopamine and motivation. Neuropsychopharmacology 2016; 41: 2830-8.
25. Cuello A. Nerve growth factor. In: Stolerman IP, Price LH, editors. Encyclopedia of psychopharmacology. Berlin: Springer Berlin Heidelberg; 2013. p. 1-9.
26. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 2010; 40: 230-5.
27. Cuello AC, Bruno MA, Bell KF. NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Curr Alzheimer Res 2007; 4: 351-8.
28. Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. J Alzheimers Dis 2014; 39: 477-85.
29. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, et al. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis 2010; 21: 843-51.
30. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
31. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281: 1401-6.
32. de Bruijn RFAG, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer's disease. BMC Medicine 2014; 12: 130.
33. Deardorff WJ, Grossberg GT. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease. Expert Opin Pharmacother 2016; 17: 1789-800.
34. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72: 1555-61.
35. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 705-12.
36. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30: 113-21.
37. Dubelaar EJ, Verwer RW, Hofman MA, Van Heerikhuize JJ, Ravid R, Swaab DE. ApoE epsilon4 genotype is accompanied by lower metabolic activity in nucleus basalis of Meynert neurons in Alzheimer patients and controls as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 2004; 63: 159-69.
38. Dubois B, Chupin M, Hampel H, Lista S, Cavedo E, Croisile B, et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimers Dement 2015; 11: 1041-9.
39. Ebmeier KP, Hunter R, Curran SM, Dougal NJ, Murray CL, Wyper DJ, et al. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 1992; 108: 103-9.
40. Engelhardt B, Carare RO, Bechmann I, Flugel A, Laman JD, Weller RO. Vascular, glial, and lymphatic immune gateways of the central nervous system. Acta Neuropathol 2016; 132: 317-38.
41. Espada S, Rojo AI, Salinas M, Cuadrado A. The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neurotransmission with neuroprotection. J Neurochem 2009; 110: 1107-19.
42. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-41.
43. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013; 19: 745-52.
44. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010; 32: 1234-51.
45. Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-44.
46. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501-12.
47. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009; 24: 479-88.
48. Field RH, Gossen A, Cunningham C. Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: reconciling inflammatory and cholinergic hypotheses of delirium. J Neurosci 2012; 32: 6288-94.
49. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014; 43: 604-15.
50. Francis PT, Ramírez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010; 59: 221-9.
51. Franz CE, Barker JC, Kravitz RL, Flores Y, Krishnan S, Hinton L. Nonmedical influences on teh use of cholinesterase inhibitors in dementia care. Alzheimer Dis Assoc Disord 2007; 21: 241-8.
52. Geaney DP, Soper N, Shepstone BJ, Cowen PJ. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet 1990; 335: 1484-7.
53. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006; 10: 417-29.
54. Geula C, Mesulam M. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease. New York, NY: Raven Press; 1994. p. 263-94.
55. Geula C, Mesulam M, Saroff D, Wu C. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J Neuropath Exp Neurol 1998; 57: 63-75.
56. Geula C, Nagykery N, Nicholas A, Wu CK. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 2008; 67: 309-18.
57. Giacobini E. Alzheimer disease, from molecular biology to therapy. Adv Exp Med Biol 1997; 429: 235-45.
58. Giacobini E. Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? Aging 2001; 13: 247-55.
59. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm Suppl 2002; 62: 181-7.
60. Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, et al. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement 2011; 7: 579-92.
61. Graff-Radford J, Boeve BF, Pedraza O, Ferman TJ, Przybelski S, Lesnick TG, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012; 135 (Pt 8): 2470-7.
62. Gray S, Andreasen ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Interm Med 2015; 175: 401-7.
63. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-25.
64. Hartig W, Saul A, Kacza J, Grosche J, Goldhammer S, Michalski D, et al. Immunolesion-induced loss of cholinergic projection neurones promotes beta-amyloidosis and tau hyperphosphorylation in the hippocampus of triple-transgenic mice. Neuropathol Appl Neurobiol 2014; 40: 106-20.
65. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162: 676-82.
66. Hashimoto M, Yatabe Y, Kaneda K, Honda K, Ikeda M. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease. Psychogeriatrics 2009; 9: 196-203.
67. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995; 273: 1354-9.
68. Higley MJ, Soler-Llavina GJ, Sabatini BL. Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration. Nat Neurosci 2009; 12: 1121-8.
69. Hollingworth SA, Byrne GJ. Prescribing trends in cognition enhancing drugs in Australia. Int Psychogeriatr 2011; 23: 238-45.
70. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17: 1236-48.
71. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol 2015; 14: 1171-81.
72. Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, et al. Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. PLoS One 2012; 7: e36893.
73. Ikonomovic MD, Abrahamson EE, Isanski BA, Wuu J, Mufson EJ, DeKosky ST. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 2007; 64: 1312-17.
74. Iulita MF, Bistue Millon MB, Pentz R, Aguilar LF, Do Carmo S, Allard S, et al. Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. Neurobiol Dis 2017; 108: 307-23.
75. Iulita MF, Caraci F, Cuello AC. A link between nerve growth factor metabolic deregulation and amyloid-beta-driven inflammation in down syndrome. CNS Neurol Disord Drug Targets 2016a; 15: 434-47.
76. Iulita MF, Cuello AC. Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. Trends Pharmacol Sci 2014; 35: 338-48.
77. Iulita MF, Ower A, Barone C, Pentz R, Gubert P, Romano C, et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement 2016b; 12: 1132-48.
78. Izquierdo I. Mechanism of action of scopolamine as an amnestic. Trends Pharmacol Sci 1989; 10: 175-7.
79. Jaworski T, Dewachter I, Lechat B, Gees M, Kremer A, Demedts D, et al. GSK-3/b kinases and amyloid production in vivo. Nature 2011; 480: E4-5; discussion E6.
80. Jelic V, Winblad B. Alzheimer disease. Donepezil and nursing home placement-benefits and costs. Nat Rev Neurol 2016; 12: 11-13.
81. Jiang S, Li Y, Zhang C, Zhao Y, Bu G, Xu H, et al. M1 muscarinic acetylcholine receptor in Alzheimer's disease. Neurosci Bull 2014; 30: 295-307.
82. Kalkman HO, Feuerbach D. Modulatory effects of 7 nAChRs on the immune system and its relevance for CNS disorders. Cell Mol Life Sci 2016; 73: 2511-30.
83. Kerwin D, Claus TH. Severe Alzheimer's disease: treatment effects on function and care requirements. J Am Med Dir Assoc 2011; 12: 99-104.
84. Kilgard MP, Merzenich MM. Plasticity of temporal information processing in the primary auditory cortex. Nat Neurosci 1998; 1: 727-31.
85. Kolisnyk B, Al-Onaizi M, Soreq L, Barbash S, Bekenstein U, Haberman N, et al. Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer's-like pathology. Cereb Cortex 2017; 27: 3553-67.
86. Lacombe P, Sercombe R, Vaucher E, Seylaz J. Reduced cortical vasodilatory response to stimulation of the nucleus basalis of Meynert in the aged rat and evidence for a control of the cerebral circulation. Ann N Y Acad Sci 1997; 826: 410-15.
87. Lacombe P, Sercombe R, Verrecchia C, Philipson V, MacKenzie ET, Seylaz J. Cortical blood flow increases induced by stimulation of the substantia innominata in the unanesthetized rat. Brain Res 1989; 491: 1-14.
88. Lanctot KL, Aguera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement 2017; 13: 84-100.
89. Lim YY, Maruff P, Schindler R, Ott BR, Salloway S, Yoo DC, et al. Disruption of cholinergic neurotransmission exacerbates Abetarelated cognitive impairment in preclinical Alzheimer's disease. Neurobiol Aging 2015; 36: 2709-15.
90. Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc Natl Acad Sci USA 2012; 109: 10071-6.
91. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106-18.
92. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003; 216: 119-26.
93. Lovestone S, Howard R. Alzheimer's disease: a treatment in sight? J Neurol Neurosurg Psychiatry 1995; 59: 566-7.
94. Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 2011; 7: 532-9.
95. Maneno MK, Lee E, Wutoh AK, Zuckerman IH, Jackson P, Lombardo FA, et al. National patterns of dementia treatment among elderly ambulatory patients. J Natl Med Assoc 2006; 98: 430-5.
96. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985; 228: 1115-17.
97. Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol 2010; 8: 69-80.
98. McDade E, Bateman RJ. Stop Alzheimer's before it starts. Nature 2017; 547: 153-5.
99. McNamara CG, Tejero-Cantero A, Trouche S, Campo-Urriza N, Dupret D. Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat Neurosci 2014; 17: 1658-60.
100. Mesulam M. A horseradish peroxidase method for the identification of the efferents of acetyl cholinesterase-containing neurons. J Histochem Cytochem 1976; 24: 1281-5.
101. Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004; 55: 815-28.
102. Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J Comp Neurol 2013; 521: 4124-44.
103. Mewaldt SP, Ghoneim MM. The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 1979; 10: 205-10.
104. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol 2013; 169: 737-43.
105. Miranda LF, Gomes KB, Silveira JN, Pianetti GA, Byrro RM, Peles PR, et al. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study. J Alzheimers Dis 2015; 45: 609-20.
106. Mitsushima D, Mizuno T, Kimura F. Age-related changes in diurnal acetylcholine release in the prefrontal cortex of male rats as measured by microdialysis. Neuroscience 1996; 72: 429-34.
107. Moore A, Patterson C, Lee L, Vedel I, Bergman H; Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. Can Fam Physician 2014; 60: 433-8.
108. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995; 6: 633-6.
109. Mori S. Responses to donepezil in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci 2002; 977: 493-500.
110. Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm 2008; 14: 451-61.
111. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008; 8: 1703-18.
112. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7.
113. Nordberg A, Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986; 72: 115-19.
114. O'Brien JT, Burns A; BAP Dementia Consensus Group. Clinical practice with antidementia drugs a revised second consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 997-1019.
115. Oremus M, Wolfson C, Bergman H, Vandal AC. Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease. Can J Aging 2007; 26: 139-48.
116. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Réglat A, Dartigues JF. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 2008; 17: 655-60.
117. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977a; 1: 189.
118. Perry EK, Perry RH, Blessed G, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia: CAT and GAD activities in necropsy tissue. J Neurol Sci 1977b; 34: 247-65.
119. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457-9.
120. Petersen RC. Scopolamine induced learning failures in man. Psychopharmacology 1977; 52: 283-9.
121. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018; 90: 126-35.
122. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-88.
123. Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, et al. Pre-and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol 2011; 122: 49-60.
124. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs 2012; 72: 789-802.
125. Power AE. Slow-wave sleep, acetylcholine, and memory consolidation. Proc Natl Acad Sci USA 2004; 101: 1795-6.
126. Ramos-Rodriguez JJ, Pacheco-Herrero M, Thyssen D, Murillo-Carretero MI, Berrocoso E, Spires-Jones TL, et al. Rapid b-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. J Neuropath Exp Neurol 2013; 72: 272-85.
127. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
128. Ray R, Prettyman R. When do we discontinue anti-dementia drugs? Views expressed by clinicians in a national survey within the United Kingdom. Int Psychogeriatr 2013; 25: 1559-60.
129. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011; 26 (Suppl 3): 321-9.
130. Reitz C. Toward precision medicine in Alzheimer's disease. Ann Transl Med 2016; 4: 107.
131. Richter N, Beckers N, Onur OA, Dietlein M, Tittgemeyer M, Kracht L, et al. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease. Brain 2018; 141: 903-15.
132. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 2016; 73: 721-32.
133. Robinson M, Rowett D, Leverton A, Mabbott V. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf 2009; 18: 659-64.
134. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009; 1: 7.
135. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012; 1-55. doi: 10.1002/ 14651858.CD009132.pub2.
136. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Pharmacol 2015; 80: 209-20.
137. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neuro 2011; 11: 21.
138. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 2015; 15: 31.
139. Salehi A, Dubelaar EJ, Mulder M, Swaab DF. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc Natl Acad Sci USA 1998; 95: 11445-9.
140. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63: 651-7.
141. Sassin I, Schultz C, Thal DR, Ruöb U, Arai K, Braak E, et al. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 2000; 100: 259-69.
142. Sato A, Sato Y. Cerebral cortical vasodilatation in response to stimulation of cholinergic fibres originating in the nucleus basalis of Meynert. J Auton Nerv Syst 1990; 30: S137-40.
143. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221: 555-63.
144. Schmitz TW, Spreng RN; Alzheimer's Disease Neuroimaging Initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimers pathology. Nat Commun 2016; 7: 13249.
145. Schoenmakers B, Buntinx F, De Lepeleire J. Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver? Fam Pract 2009; 26: 279-86.
146. Schroder H, Giacobini E, Struble RG, Zilles K, Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 1991; 12: 259-62.
147. Segal-Gidan F, Cherry D, Jones R, Williams B, Hewett L, Chodosh J, et al. Alzheimer's disease management guideline: update 2008. Alzheimers Dement 2011; 7: e51-9.
148. Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017; 549: 523-7.
149. Shirayama Y, Takahashi M, Oda Y, Yoshino K, Sato K, Okubo T, et al. rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. Brain Imaging Behav 2017; 1-12. doi: 10.1007/s11682-017-9803-y.
150. Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, et al. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord 2011; 31: 173-8.
151. Snyder PJ, Santos CY, Getter C, Schindler R, Ott BR, Salloway S, et al. Cholinergic deficit as a predictor of disease progression: amyloid accumulation and episodic memory decline in a 27-month preclinical AD study. Alzheimers Dement 2017; 13: P1232-3.
152. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13.
153. Summers WK, Majorski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 1986; 315: 1241-5.
154. Szutowicz A, Bielarczyk H, Jankowska-Kulawy A, Pawelczyk T, Ronowska A. Acetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseases. Neurochem Res 2013; 38: 1523-42.
155. Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schück S, et al. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). Pharmacoepidemiol Drug Saf 2012; 21: 1005-12.
156. Triaca V, Calissano P. Impairment of the nerve growth factor pathway driving amyloid accumulation in cholinergic neurons: the incipit of the Alzheimer's disease story? Neural Regen Res 2016; 11: 1553-6.
157. Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer's disease: systematic review and network metaanalysis. J Am Geriatr Soc 2018; 66: 170-178.
158. Turnbull MT, Boskovic Z, Coulson EJ. Acute down-regulation of BDNF signaling does not replicate exacerbated amyloid-b levels and cognitive impairment induced by cholinergic basal forebrain lesion. Front Mol Neurosci 2018; 11: 51.
159. Uusvaara J, Pitkala KH, Tienari PJ, Kautiainen H, Tilvis RS, Strandberg TE. Association between anticholinergic drugs and apolipoprotein E epsilon4 allele and poorer cognitive function in older cardiovascular patients: a cross-sectional study. J Am Geriatr Soc 2009; 57: 427-31.
160. Van Beek AH, Claassen JA. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease. Behav Brain Res 2011; 221: 537-42.
161. van den Bussche H, Kaduszkiewicz H, Koller D, Eisele M, Steinmann S, Glaeske G, et al. Antidementia drug prescription sources and patterns after the diagnosis of dementia in Germany: results of a claims data-based 1-year follow-up. Int Clin Psychopharmacol 2011; 26: 225-31.
162. Vaucher E, Borredon J, Bonvento G, Seylaz J, Lacombe P. Autoradiographic evidence for flow-metabolism uncoupling during stimulation of the nucleus basalis of meynert in the conscious rat. J Cereb Blood Flow Metab 1997; 17: 686-94.
163. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002; 13: 83-7.
164. Wallin AK, Andreasen N, Eriksson S, Båtsman S, Nasman B, Ekdahl A, et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-60.
165. Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, et al. APOE-e4 carrier status and donepezil response in patients with Alzheimer's disease. J Alzheimers Dis 2015; 47: 137-48.
166. Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist 2011; 51: 17-27.
167. Welt T, Kulic L, Hoey SE, McAfoose J, Spani C, Chadha AS, et al. Acute effects of muscarinic M1 receptor modulation on AbetaPP metabolism and amyloid-beta levels in vivo: a Microdialysis Study. J Alzheimers Dis 2015; 46: 971-82.
168. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, et al. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement 2010; 6: 412-19.
169. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-6.
170. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9.
171. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70: 2024-35.
172. Zilkens RR, Duke J, Horner B, Semmens JB, Bruce DG. Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010. Alzheimers Dement 2014; 10: 310-18.